Analogues of gonadotropin-releasing hormone in the treatment of women with uterine fibroids

Dovletkhanova E.R., Abakarova P.R., Mezhevitinova E.A.

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia

Uterine fibroids are a common gynecological disease in women of reproductive age which can cause significant clinical problems. The development and growth of uterine fibroids involve a number of pathogenetic factors including genetic and epigenetic factors, an imbalance of steroid hormones, cell proliferation and apoptosis, etc. Uterine fibroids can develop due to a number of factors directly related to the activity of the ovaries. Estradiol and progesterone play a significant role. Various tactics for managing patients with uterine fibroids include not only surgical, but also conservative treatment methods. Therefore, it is possible to make treatment individualized taking into account the symptoms, the size and location of fibroids, as well as the age, needs and desires of the patient to preserve fertility and achieve motherhood. Gonadotropin-releasing hormone agonists (aGnRH) were among the first medications recommended for the treatment of fibroids. AGnRH is a number of effective drugs that affect not only the symptoms caused by uterine fibroids, but also impact the size of myomatous nodes. The representative of aGnRH is buserelin, a synthetic analogue of gonadotropin-releasing hormone. The effectiveness of conservative therapy of uterine fibroids using buserelin has been evaluated in a number of studies.
Conclusion: The use of aGnRH allows one to control the symptoms of uterine fibroids, such as bleeding and pain syndrome, reduce the volume of the myomatous node, which may lead to a subsequent reduction in the volume of surgical intervention. Buserelin, as the form of aGnRH, is effectively used not only in the treatment of symptomatic uterine fibroids before subsequent surgical intervention, but it can be used in complex therapy before pregnancy planning by ART methods in women with uterine fibroids and infertility.

Authors’ contributions: Dovletkhanova E.R., Abakarova P.R., Mezhevitinova E.A. – developing the concept and design of the study, collecting and processing the material, selection of literature on the stated issue, writing the text, editing.
Conflicts of interest: Authors declare lack of the possible conflicts of interests.
Funding: The study was conducted without sponsorship.
For citation: Dovletkhanova E.R., Abakarova P.R., Mezhevitinova E.A. Analogues of gonadotropin-releasing hormone in the treatment of women with uterine fibroids.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (3): 172-178 (in Russian)


uterine fibroids
gonadotropin-releasing hormone
gonadotropin-releasing hormone agonists


  1. Савельева Г.М., Сухих Г.Т., Серов В.Н, Радзинский В.Е., Манухин И.Б., ред. Национальное руководство. Гинекология. М: ГЭОТАР-­Медиа; 2022. 1008 с. [Savelyeva G.M., Sukhikh G.T., Serov V.N., Radzinsky V.E., Manukhin I.B., eds. National Guide. Gynecology. Moscow: GEOTAR-Media; 2022. 1008p. (in Russian)].
  2. Адамян Л.В., ред. Миома матки: диагностика, лечение и реабилитация. Клинические рекомендации по ведению больных. 2015. [Adamyan L.V., ed. Uterine myoma: diagnosis, treatment and rehabilitation. Clinical guidelines for the management of patients. 2015. (in Russian)].
  3. Tinelli A., Kosmas I., Medvediev M.V., Malvasi A., Morciano A., Sparić R., Mynbaev O.A. Myomectomy in adult women of reproductive age: a propensity score-matched study for pregnancy rates. Arch. Gynecol. Obstet. 2023; 308(4): 1351-60.
  4. Reis F.M., Bloise E., Ortiga-Carvalho T.M. Hormones and pathogenesis of uterine fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2016; 34: 13-24.
  5. Довлетханова Э.Р., Межевитинова Е.А., Прилепская В.Н. Неоперативное лечение миомы матки. Эффективность использования селективного модулятора прогестероновых рецепторов. Медицинский совет. 2019; 7: 13-20. [Dovletkhanova E.R., Mezhevitinova E.A., Prilepskaya V.N. Non-operative treatment of uterine fibroids. The effectiveness of using a selective progesterone receptor modulator. Medical Council. 2019; (7): 13-20. (in Russian)].
  6. Адамян Л.В., Сонова М.М, Шамугия Н.М. Опыт применения селективных модуляторов рецепторов прогестерона в лечении миомы матки (обзор литературы). Проблемы репродукции. 2014; (4): 34-8. [Adamyan L.V., Sonova M.M., Shamugia N.M. The experience of uterine fibroids treatment with selective progesterone-receptor modulator. Russian Journal of Human Reproduction. 2014; (4): 34-8 (in Russian)].
  7. El-Balat A., DeWilde R.L., Schmeil I., Tahmasbi-Rad M., Bogdanyova S., Fathi A., Becker S. Modern myoma treatment in the last 20 years: a review of the literature. Biomed. Res. Int. 2018; 2018: 4593875.
  8. Moravek M.B., Bulun S.E. Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution. Curr. Opin. Obstet. Gynecol. 2015; 27(4): 276-83.
  9. Lethaby A.E., Vollenhoven B.J. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2008; 22(2): 307-31.
  10. Yang Q., Ciebiera M., Bariani M.V., Ali M., Elkafas H., Boyer T.G., Al-Hendy A. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr. Rev. 2022; 43(4): 678-719.
  11. Министерство здравоохранения Российской Федерации. Миома матки. Клинические рекомендации. 2020. [Ministry of Health of the Russian Federation. Uterine fibroids. Clinical guidelines. 2020. (in Russian)].
  12. De Leo V., Morgante G., La Marca A., Musacchio M.C., Sorace M., Cavicchioli C., Petraglia F. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Saf. 2002; 25(11): 759-79.
  13. Donnez J., Tomaszewski J., Vázquez F., Bouchard P., Lemieszczuk B., Baró F. et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012; 366(5): 421-32.
  14. Islam M.S., Protic O., Giannubilo S.R., Toti P., Tranquilli A.L., Petraglia F. et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J. Clin. Endocrinol. Metab. 2013; 98(3): 921-34.
  15. Адамян Л.В., Зайратьянц О.В., Тихомиров А.Л., Манухин И.Б., Опаленов К.В., Казенашев В.В., Алиева Т.Д. Антипролиферативное и проапоптотическое действие селективного модулятора рецепторов прогестерона улипристала на лейомиому матки in vivo. Проблемы репродукции. 2014; (3): 41-4. [Adamyan L.V., Zairat’yants O.V., Tikhomirov A.L., Manukhin I.B., Opalenov K.V., Kazenashev V.V., Alieva T.D. Antiproliferative and proapoptotic effects of the selective progesterone receptor modulator ulipristal on uterine leiomyoma in vivo. Russian Journal of Human Reproduction. 2014; (3): 41-4 (in Russian)].
  16. Лебедева Я.А., Молчанов О.Л., Байбуз Д.В., Галиуллина Л.А. Оценка качества жизни женщин репродуктивного возраста после лечения миомы матки с применением антигестагенов. Медицинский вестник Башкортостана. 2019;14(82): 16-21. [Lebedeva Ya.A., Molchanov O.L., Baibuz D.V., Galiullina L.A. Assessment of the quality of life of women of reproductive age after treatment of uterine fibroids with the use of antigestogens. Medical Bulletin of Bashkortostan. 2019;4(82): 16-21 (in Russian)].
  17. Moroni R.M., Martins W.P., Dias S.V., Vieira C.S., Ferriani R.A., Nastri C.O., Brito L.G. Combined oral contraceptive for treatment of women with uterine fibroids and abnormal uterine bleeding: a systematic review. Gynecol. Obstet. Invest. 2015; 79(3): 145-52.
  18. Wellington K., Wagstaff A.J. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003; 63(13):1417-33.
  19. Lethaby A., Duckitt K., Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2013; 31(1): CD000400.
  20. Baird D.D., Hill M.C., Schectman J.M., Hollis B.W. Vitamin d and the risk of uterine fibroids. Epidemiology. 2013; 24(3): 447-53.
  21. Singh S.S., Belland L. Contemporary management of uterine fibroids: focus on emerging medical treatments. Curr. Med. Res. Opin. 2015; 31(1): 1-12.
  22. Kashani B.N., Centini G., Morelli S.S., Weiss G., Petraglia F. Role of medical management for uterine leiomyomas. Best Pract. Res. Clin. Obstet. Gynaecol. 2016; 34: 85-103.
  23. Sankaran S., Manyonda I.T. Medical management of fibroids. Best. Pract. Res. Clin. Obstet. Gynaecol. 2008; 22(4): 655-76.
  24. Pritts E.A., Parker W.H., Olive D.L. Fibroids and infertility: an updated systematic review of the evidence. Fertil. Steril. 2009; 91(4): 1215-23.
  25. Khan A.T., Shehmar M., Gupta J.K. Uterine fibroids: current perspectives. Int. J. Womens Health. 2014; 6: 95-114.
  26. Doherty L., Mutlu L., Sinclair D., Taylor H. Uterine fibroids: clinical manifestations and contemporary management. Reprod. Sci. 2014; 21(9): 1067-92.
  27. Donnez J., Vázquez F., Tomaszewski J., Nouri K., Bouchard P., Fauser B.C. et al.; PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil. Steril. 2014; 101(6): 1565-73.e1-18.
  28. Segars J.H., Parrott E.C., Nagel J.D., Guo X.C., Gao X, Birnbaum L.S. et al. Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations. Hum. Reprod. Update. 2014; 20(3): 309-33.
  29. Biglia N., Carinelli S., Maiorana A., D'Alonzo M., Lo Monte G., Marci R. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des. Devel. Ther. 2014;8:285-92.
  30. Chegini N., Rong H., Dou Q., Kipersztok S., Williams R.S. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J. Clin. Endocrinol. Metab. 1996; 81(9): 3215-21.
  31. Halder S.K., Osteen K.G., Al-Hendy A. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum. Reprod. 2013; 28(9):2407-16.
  32. Wiznitzer A., Marbach M., Hazum E., Insler V., Sharoni Y., Levy J. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem. Biophys. Res. Commun. 1988; 152(3): 1326-31.
  33. Owen C., Armstrong A.Y. Clinical management of leiomyoma. Obstet. Gynecol. Clin. North. Am. 2015; 42(1): 67-85.
  34. Lethaby A., Vollenhoven B., Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst. Rev. 2001; (2): CD000547.
  35. Chang W.C., Chu L.H., Huang P.S., Huang S.C., Sheu B.C. Comparison of laparoscopic myomectomy in large myomas with and without leuprolide acetate. J. Minim. Invasive. Gynecol. 2015; 22(6): 992-6.
  36. Muzii L., Boni T., Bellati F., Marana R. Ruggiero A., Zullo M.A. et al. GnRH analogue treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study. Fertil. Steril. 2010; 94(4): 1496-99.
  37. Perrone A.M., Pozzati F., Di Marcoberardino B., Rossi M., Procaccini M., Pellegrini A. et al. Single or repeated gonadotropin-releasing hormone agonist treatment avoids hysterectomy in premenopausal women with large symptomatic fibroids with no effects on sexual function. J. Obstet. Gynaecol Res. 2014; 40(1): 117-24.
  38. Talaulikar V.S., Manyonda I. Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 165(2): 135-40.
  39. Vilos G.A., Allaire C., Laberge P.Y., Leyland N., SPECIAL CONTRIBUTORS. The management of uterine leiomyomas. J. Obstet. Gynaecol. Can. 2015; 37(2): 157-78.
  40. Moro E., Degli Esposti E., Borghese G., Manzara F., Zanello M., Raimondo D. et al. The impact of hormonal replacement treatment in postmenopausal women with uterine fibroids: a state-of-the-art review of the literature. Medicina (Kaunas). 2019; 55(9): 549.
  41. Giuliani E., As-Sanie S., Marsh E.E. Epidemiology and management of uterine fibroids. Int. J. Gynaecol Obstet. 2020; 149(1): 3-9.
  42. Morris E.P., Rymer J., Robinson J., Fogelman I. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil. Steril. 2008; 89(2): 421-8.
  43. Kanelopoulos N., Dendrinos N., Oikonomou A., Panagopoulos P., Markussis V. Doppler-ultrasound as a predictor of uterine fibroid response to GnRH therapy. Int. J. Gynaecol. Obstet. 2003; 82(1): 41-7.
  44. Takahashi N., Yoshino O., Hiraike O., Maeda E., Nakamura M., Hori M. et al. The assessment of myometrium perfusion in patients with uterine fibroid by arterial spin labeling MRI. Springerplus. 2016; 5(1): 1907.
  45. Хворостухина Н.Ф., Островская А.Е., Рогожина И.Е., Новичков Д.А., Степанова Н.Н. Особенности маточной гемодинамики и системы гемостаза при миоме, осложненной геморрагическим синдромом. Акушерство и гинекология. 2016; 6: 87-93. [Khvorostukhina N.F., Ostrovskaya A.E., Rogozhina I.E., Novichkov D.A., Stepanova N.N. The specific features of uterine hemodynamics and hemostatic system in myoma complicated by hemorrhagic syndrome. Obstetrics and Gynecology. 2016; (6): 87-93. (in Russian)].
  46. Девятова Е.А., Цатурова К.А., Вартанян Э.В., Петухова Н.Л., Зинченко Н.А., Михайлюкова А.С. Консервативная терапия миомы матки и спонтанная беременность у пациенток с репродуктивными потерями в анамнезе. Доктор.Ру. 2017; 7(136): 21-7. [Devyatova E.A., Tsaturova K.A., Vartanyan E.V., Petukhova N.L., Zinchenko N.A., Mikhailyukova A.S. Conservative therapy of uterine fibroids and spontaneous pregnancy in patients with a history of reproductive losses. 2017; 7(136): 21-7 (in Russian)].
  47. Девятова Е.А., Цатурова К.А., Вартанян Э.В., Петухова Н.Л., Маркин А.В. Консервативная терапия миомы матки перед лечением бесплодия методом экстракорпорального оплодотворения. Акушерство и гинекология. 2017; 3: 131-8. [Devyatova E.A., Tsaturova K.A., Vartanyan E.V., Petukhova N.L., Markin A.V. Conservative therapy of uterine fibroids prior to in vitro fertilization treatment for infertility. Obstetrics and Gynecology. 2017; (3): 131-8. (in Russian)].

Received 17.11.2023

Accepted 17.12.2023

About the Authors

Elmira R. Dovletkhanova, PhD, Senior Researcher, Scientific Polyclinic Department, Academician V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,
+7(495)438-69-34,, 117997, Russia, Moscow, Ac. Oparin str., 4.
Patimat R. Abakarova, PhD, Researcher, Scientific Polyclinic Department, Academician V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,
+7(495)438-69-34,, 117997, Russia, Moscow, Ac. Oparin str., 4.
Elena A. Mezhevitinova, PhD, Leading Researcher, Scientific Polyclinic Department, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, +7(495)438-69-34,, 117997, Russia, Moscow, Ac. Oparin str., 4.

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.